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Abstract
Background: There have been few reports on the role of Fc receptors (FcRs) and immunoglobulin G (IgG) in
asthma. The purpose of this study is to clarify the role of inhibitory FcRs and antigen presenting cells (APCs) in
pathogenesis of asthma and to evaluate antigen-transporting and presenting capacity by APCs in the
tracheobronchial mucosa.
Methods: In FcgRIIB deficient (KO) and C57BL/6 (WT) mice, the effects of intratracheal instillation of antigen-specific
IgG were analysed using the model with sensitization and airborne challenge with ovalbumin (OVA). Thoracic
lymph nodes instilled with fluorescein-conjugated OVA were analysed by fluorescence microscopy. Moreover, we
analysed the CD11c+ MHC class II+ cells which intaken fluorescein-conjugated OVA in thoracic lymph nodes by
flow cytometry. Also, lung-derived CD11c+ APCs were analysed by flow cytometry. Effects of anti-OVA IgG1 on
bone marrow dendritic cells (BMDCs) in vitro were also analysed. Moreover, in FcgRIIB KO mice intravenously
transplanted dendritic cells (DCs) differentiated from BMDCs of WT mice, the effects of intratracheal instillation of
anti-OVA IgG were evaluated by bronchoalveolar lavage (BAL).
Results: In WT mice, total cells and eosinophils in BAL fluid reduced after instillation with anti-OVA IgG1. Anti-OVA
IgG1 suppressed airway inflammation in hyperresponsiveness and histology. In addition, the number of the
fluorescein-conjugated OVA in CD11c+ MHC class II+ cells of thoracic lymph nodes with anti-OVA IgG1 instillation
decreased compared with PBS. Also, MHC class II expression on lung-derived CD11c+ APCs with anti-OVA IgG1
instillation reduced. Moreover, in vitro, we showed that BMDCs with anti-OVA IgG1 significantly decreased the T
cell proliferation. Finally, we demonstrated that the lacking effects of anti-OVA IgG1 on airway inflammation on
FcgRIIB KO mice were restored with WT-derived BMDCs transplanted intravenously.
Conclusion: Antigen-specific IgG ameliorates allergic airway inflammation via FcgRIIB on DCs.
Background
It is estimated that as many as 300 million people of all
ages suffer from bronchial asthma, and that asthmatic
patients are increasing by 50% per decade worldwide
[1]. The mucosa of respiratory tracts are replete with
organized follicles and scattered antigen reactive or sen-
sitized lymphoid elements, including B cells, T cells,
plasma cells, dendritic cells (DCs) and a variety of other
cellular elements against invading pathogens. The
mucosal surfaces are also known to possess critical
immunoglobulins, such as IgA, IgM and IgG.
Bronchial asthma is characterized by allergic inflamma-
tion of the bronchial mucosa, in addition to airway
hyperresponsiveness (AHR), and elevated titers of circu-
lating IgE. In asthmatic patients, antigen-specific IgE
binds to FcεRI on mast cells and FcεRII on eosinophils
and macrophages [2]. As a result of IgE cross-linking
after antigen inhalation, an immediate allergic reaction is
induced. On the other hand, the T helper 2 (Th2)-type
immune response plays an important role in the late-
phase reaction. When the inhaled allergen is recognized
and presented by antigen presenting cells (APCs) in the
airway, T cells are activated and differentiate from Th0
cells into Th2-type cells. Th2-type cells produce Th2
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cytokines such as IL-4, IL-5 and IL-13 [3]. IL-4 activates
the production of IgE in B cells, IL-5 increases the num-
ber of eosinophils in the airway, and IL-13 is involved in
AHR and mucus secretion in the airway.
With regard to the study of immunoglobulins in asthma,
there have been some reports on a novel anti-IgE therapy
that exerts its action by reducing the amount of free IgE to
bind to effector cells [4-6]. However, this approach cannot
completely reduce circulating IgE, and cannot control the
initial cascade of asthma pathogenesis. It is also known
that IgG is present in the airway lumen and submucosa
under normal conditions [7]. Although antigen-specific
IgG is induced after antigen inhalation, its role in bronchial
asthma remains unknown. OVA-specific IgG in rat-sera,
such as IgG1 and IgG2a, is reported to increase on day 21
after OVA inhalation in asthmatic models induced by
OVA [8]. Platts-Mills et al. demonstrated a progressive
increase in specific serum IgG titers with extended expo-
sure and a prevalence of Th2 cytokine-dependent IgG in
cats and dogs [9]. Immunotherapy by allergen vaccination
is reported to increase antigen-specific IgG titers in allergy
patients [10], thus suggesting that antigen-specific IgG may
exert a protective effect against allergies and bronchial
asthma. However, the mechanism that antigen-specific IgG
suppresses allergic airway inflammation is unclear.
There have been many studies on Fc receptors (FcRs),
which are the receptors for the Fc portion of immuno-
globulin [11-13]. FcRs are known to be associated with
the immune responses in antibody-dependent cellular
cytotoxicity or hypersensitivity [12,13]. Activating type
FcRs consist of the FcR g-chain, which has an immunor-
eceptor tyrosine-based activation motif (ITAM) in cyto-
sol, while FcgRIIB is the only immunosuppressive FcR
having an immunoreceptor tyrosine-based inhibitory
motif (ITIM) [14-16]. FcgR and FcgRIIB on effector
cells, such as macrophages or DCs regulate the immune
response by influencing one another, and FcgRIIB on B
cells was recently reported to negatively regulate the
production of antibody [17]. FcgRIIB is present on var-
ious types of hematopoietic cells including macrophages,
neutrophils and DCs [18]. DCs play an important role
by presenting antigens to naive T cells in allergic airway
inflammation [19-21]. Moreover, expression of FcgRs on
DCs is reported to be important during the sensitization
phase for the development of allergen-induced AHR and
inflammation as described previously [22]. Therefore,
anti-OVA IgG was intratracheally instilled during the
sensitization phase in allergic murine model to analyse
the role of FcRs and APCs in pathogenesis of asthma.
Methods
Mice
FcgRIIB-deficient [23] mice (FcgRIIB KO) of a C57BL/6J
(wild type; WT) background were kindly provided by Prof.
Toshiyuki Takai (Tohoku University). Mice transgenic for
the OVA323-339 specific T cell receptor (OT-II mice) on a
C57BL/6J background [24] were used. WT mice were pur-
chased from CLEA Japan (Tokyo, Japan). All animal
experiments were performed in accordance with the
Guidelines for Animal Experimentation at Kobe University
Graduate School of Medicine. Our research was approved
by the Institutional Animal Care and Use Committee and
was carried out according to Kobe University Animal
Experimentation Regulations (P070703R).
Agents
The following drugs and chemicals were purchased com-
mercially: endotoxin-free OVA (Sigma-Aldrich, St. Louis,
MO, USA); aluminium hydroxide (alum) (Sigma-
Aldrich); acetyl-b-methylcholine chloride (Sigma-
Aldrich); fluorescein-conjugated OVA (Invitrogen,
Eugene, OR, USA); Albumin, from Bovine Serum (Wako
Pure Chemical Industries, Osaka, Japan); purified rat
anti-mouse CD16/CD32 antibody (BD Biosciences,
Franklin Lakes, N J, USA); phycoerythrin (PE)-hamster
anti-mouse CD11c antibody (BD Biosciences); biotin-
mouse anti-mouse I-A[b] antibody (BD Biosciences);
streptavidin allophycocyanin (BD Biosciences); Anti-
MHC class II-FITC (Miltenyi Biotec, Gladbach, Ger-
many); 7-Amino-Actinomycin D (7-AAD) (BD Bios-
ciences); collagenase D (Roche Molecular Biochemicals,
Mannheim, Germany); and deoxyribonuclease (DNase) I
(bovine pancreas; Wako); ethylenediaminetetraacetic acid
(EDTA), disodium salt (Wako); Roswell Park Memorial
Institute (RPMI)-1640 (Sigma-Aldrich); 2-mercaptoetha-
nol (Sigma-Aldrich); penicillin-streptomycin solution
(Sigma-Aldrich); granulocyte macrophage colony-stimu-
lating factor (GM-CSF) (Wako Pure Chemical Indus-
tries); CD4 microbeads (Miltenyi Biotec, Gladbach,
Germany); and OVA peptide 323-339 (Genway Biotech,
Inc., San Diego, CA, USA).
Establishment of anti-OVA IgG
Anti-OVA IgG1 and anti-OVA IgG2a in endotoxin-free
condition were kindly provided by Hajime Karasuyama
(Tokyo Medical and Dental University Graduate School).
A panel of hybridomas secreting OVA-specific IgG
monoclonal antibodies was prepared from splenocytes
isolated from mice that immunized intraperitoneally 14
days before with OVA with injection alum plus B. pertus-
sis toxin or complete Freund’s adjuvant, as Ishikawa et al.
described previously [25]. Concentrations of anti-OVA
IgG1 and IgG2a were assayed by enzyme-linked immu-
nosorbent assay (ELISA), as described previously [26].
Sensitization and antigen challenge
Six- to ten-week-old female mice were sensitized by
intraperitoneal injections of 10 μg of OVA with 1 mg of
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alum on days 0, 7 and 14. They were then exposed to
1% OVA diluted in sterile phosphate-buffered saline
(PBS) for 30 min on 2 consecutive days with an ultraso-
nic nebulizer (NE-U12) (OMRON, Tokyo, Japan). Each
subclass of anti-OVA IgG (10 μg/50 μl) was diluted in
sterile PBS and instilled intratracheally on 25th days
before OVA challenge. As compared to the controls,
non-specific IgG was intratracheally instilled instead of
anti-OVA IgG. All mice were analyzed 24 h after the
final OVA challenge.
Bronchoalveolar lavage (BAL)
BAL fluid was obtained by instilling 0.8 ml PBS and
aspirating three times (recovery >85%) on 24 h after the
final antigen challenge. BAL fluid was centrifuged at
3,000 × g for 5 min (at 4°C), and the supernatants were
stored at -80°C. Total cells in BAL fluid were counted
with a hemocytometer. On cytospin preparations stained
with Diff-Quick (Sysmex Corporation, Kobe, Japan), dif-
ferential cell counts were determined by classification of
200 cells based on standard morphology.
ELISA
Levels of IL-4, IL-5, IL-13 and IFN-g in BAL fluid were
determined using ELISA kits (Invitrogen, R&D systems,
Minneapolis, MN, USA) according to the manufacturer’s
instructions. The absorbance of each sample was mea-
sured at 450 nm with iMark™ microplate reader
(BioRAD, Tokyo, Japan).
Histopathology
Murine lungs were intratracheally instilled with 10%
buffered formalin at a pressure of 20 cmH2O for 24 h
and then embedded in paraffin. Serial 4-μm sections
were stained with hematoxylin and eosin (H&E).
Measurement of airway hyperresponsiveness
At 24 h after the final aerosol challenge, AHR was assessed
in conscious and unrestrained mice by means of whole
body plethysmography (Buxco Electronics, Sharon, CT,
USA) as described previously [27]. Each mouse was placed
in a plastic chamber and exposed to aerosolized PBS, fol-
lowed by increasing concentrations of aerosolized acetyl-
b-methylcholine chloride solutions (methacholine) (1.56,
3.13, 6.25, 12.5, 25, 50 μg/ml) for 3 min each. Bronchocon-
striction was recorded for an additional 5 min for each
dose of methacholine. The highest enhanced pause (Penh)
value obtained during each methacholine challenge was
expressed as a ratio against the basal Penh value in
response to PBS challenge.
Analysis of OVA transport to thoracic lymph nodes
A total of 50 μl of 10 mg/ml fluorescein-conjugated
OVA was intratracheally instilled in sensitized WT mice
one day after intratracheal instillation of 10 μg/50 μl
anti-OVA IgG1 or PBS. Thoracic lymph nodes were
analyzed 24 h after OVA challenge for 30 min by fluor-
escence microscopy in order to verify whether anti-
OVA IgG1 inhibits antigen transport to thoracic lymph
nodes in allergic airway inflammation. Moreover, we
analysed the CD11c+ cells which intaken fluorescein-
conjugated OVA in thoracic lymph nodes by flow cyto-
metry according to previous studies [28]. Lymph nodes
of OVA-sensitized and challenged mice were excised
after anti-OVA IgG1 or PBS instillation. Minced lymph
nodes were digested into single-cell suspensions with
RPMI 1640 medium supplemented with 5% fetal bovine
serum, 1 mg/ml collagenase D, 0.02 mg/ml DNase I and
5 mM EDTA for 30 min at 37°C. This was filtered
through a 70-μm cell strainer. After blocking with 3%
BSA in PBS, single-cell suspensions were pre-incubated
with Fc-receptor blocking, purified rat anti-mouse
CD16/CD32 antibodies in order to reduce nonspecific
binding. PE-hamster anti-mouse CD11c antibodies, bio-
tin-mouse anti-mouse I-A[b] antibodies and streptavi-
din-allophycocyanin (SA-APC) were used to identify
CD11c+ APCs populations in lymph nodes.
Flow cytometry of lung-derived CD11c+ cells
Lungs of OVA-sensitized and challenged mice were
excised after anti-OVA IgG1 or PBS instillation. Minced
lung tissues were digested and incubated with RPMI
1640 medium supplemented with collagenase D, DNase
I, and EDTA. The digested cells were filtered through
cell strainer, and erythrocytes were lysed with a lysing kit
(Funakoshi, Tokyo, Japan). After blocking with 3% BSA
in PBS, single-cell suspensions were also pre-incubated
with purified rat anti-mouse CD16/CD32 antibodies. PE-
hamster anti-mouse CD11c antibodies and anti-MHC
class II-FITC were used to identify murine lung CD11c+
APC populations.
Preparation of BMDCs
BMDCs were differentiated from bone marrow cells in
WT mice as described previously [29,30]. Cell culture
medium was RPMI-1640 supplemented with penicillin-
streptomycin, 2-mercaptoethanol (50 μM) and 10% FCS.
BMDCs from WT mice were cultured with 20 ng/ml
murine GM-CSF at day 0. On days 3 and 6, 20 ng/ml
GM-CSF was added to the culture fluid. On day 6,
BMDCs were employed to examine whether anti-OVA
IgG1 ameliorated the activation of BMDCs.
Effects of anti-OVA IgG1 on BMDCs in vitro
In order to investigate the effects of anti-OVA IgG1 on
the activation of BMDCs, we cultured BMDCs in the
presence of GM-CSF for 5 days. On day 6, OVA peptide
(20 μM) with or without anti-OVA IgG1 (0.1 mg/ml)
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was added to BMDCs (2 × 104) per well. On day 7,
CD4+ T-cells were isolated from the spleens of OT-II
mice using CD4 microbeads for auto-MACS (Miltenyi
Biotec, Gladbach, Germany) and CD4+ T-cells (2 × 105)
were added to each well after washing and were incu-
bated for 48 h. The number of viable cells was examined
by colorimetric assay using the WST-8 [2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium, monosodium salt] cell-counting kit
(Dojindo, Kumamoto, Japan) according to the manufac-
turer’s protocols. At 2 h after incubation with WST-8
solution, the absorbance of each well was measured at
450 nm with a reference wavelength of 655 nm [31].
Transplantation of BMDCs into FcgR IIB KO mice
FcgRIIB KO mice were sensitized and challenged as
described above. To verify the function of DCs in aller-
gic airway inflammation, BMDCs (106 cells per mouse)
cultured from WT mice were transplanted intravenously
into FcgRIIB KO mice on day 24 before instillation of
anti-OVA IgG1.
Statistical analysis
All results are expressed as means ± standard error of the
mean (SEM). A t-test was conducted in order to deter-
mine differences between two groups. As measured
values were not distributed normally and the sample size
was small, nonparametric analysis using a Mann-Whitney
U test confirmed that differences remained significant,
even if the underlying distribution was uncertain. The p
values for significance were set at 0.05 for all tests.
Results
Intratracheal instillation of anti-OVA IgG1 ameliorated
Th2 response allergic airway inflammation to a greater
degree than anti-OVA IgG 2a
In WT mice, anti-OVA IgG subclass instillation signifi-
cantly decreased the number of total cells and eosinophils
in BAL fluid as compared with PBS group, although non-
specific IgG did not decrease (Figure 1A). In particular,
anti-OVA IgG1 significantly attenuated the number of
eosinophils in BAL fluid compared with anti-OVA IgG2a
(Figure 1A). Also, IL-4, IL-5, and IL-13 in BAL fluid of
anti-OVA IgG1 instillation significantly decreased com-
pared with PBS group, on the other hand, anti-OVA IgG1
instillation increased IFN-g cytokine levels in BAL fluid
compared with PBS (Figure 1B). IL-4, IL-5, and IL-13 in
BAL fluid with anti-OVA IgG2a instillation also reduced
compared with PBS group, not more than anti-OVA IgG1
(Figure 1B). IFN-g levels in BAL fluid by instillation of
anti-OVA IgG2a showed no change compared with PBS
group (Figure 1B). H&E-stained lung tissue sections
showed increased number of eosinophils in peribronchial
and perivascular areas of asthmatic WT mice (Figure 1C).
Instillation of anti-OVA IgG suppressed the number
of inflammatory cells in the airway compared to PBS
instillation (Figure 1C). Especially, the instillation of anti-
OVA IgG1 has the most suppression among every anti-
OVA IgG. With regard to AHR, mice instilled with
anti-OVA IgG1 also showed significant inhibition when
compared to anti-OVA IgG2a (Figure 1D).
The numbers of OVA transport to thoracic lymph nodes
with anti-OVA IgG1 instillation reduced compared with PBS
In order to verify antigen transport of DCs in allergic air-
way inflammation, we analysed OVA transport from airway
mucosa to thoracic lymph nodes by fluorescence micro-
scopy. Fluorescein-conjugated OVA was seen in lymph
nodes of allergic mice instilled with PBS (Figure 2A). Fluor-
escence microscopy observation confirmed a reduction in
fluorescein-conjugated OVA in lymph nodes after instilla-
tion of anti-OVA IgG1 (Figure 2A). Additionally anti-OVA
IgG1 also reduced the number of the fluorescein-positive
CD11c+ MHC class II+ cells in thoracic lymph nodes com-
pared with PBS instilled group (Figure 2B). These results
show that anti-OVA IgG1 instillation in allergic inflamma-
tion reduced transport of OVA.
MHC class II expression on lung-derived CD11c+ APCs
with anti-OVA IgG1 instillation reduced compared with
PBS
In order to clarify the role of CD11c+ APCs in allergic
airway inflammation, we analyzed MHC class II expres-
sion on lung-derived CD11c+ APCs by flow cytometry.
MHC class II expression on lung CD11c+ APCs of WT
mice instilled with PBS increased as compared with
naïve mice (Figure 3). On the other hand, in WT mice
instilled with anti-OVA IgG1, it decreased (Figure 3).
These findings showed anti-OVA IgG1 instillation
resulted in the decrease of MHC class II+ APCs, sug-
gesting its effects on lung APCs.
Anti-OVA IgG1 ameliorated the activation of BMDCs in vitro
The optical density of T cells, as measured with a cell
counting kit, increased by addition of OVA peptide in
co-culture medium with BMDCs compared to negative
control (OVA peptide free). AntiOVA-IgG1 group sig-
nificantly decreased the T cells proliferation (Figure 4).
It means that antiOVA-IgG1 prevented BMDCs from
presenting antigens, resulting in decreasing the number
of T cells.
Intratracheal instillation of anti-OVA IgG1 increases
allergic airway inflammation in FcgRIIB KO mice
Airway inflammation showed no changes in FcgRIIB KO
mice instilled with PBS, similarly to WT mice, while
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FcgRIIB KO mice instilled with anti-OVA IgG1 signifi-
cantly deteriorated airway inflammation in BAL fluid
and histopathology (Figure 5A, B).
BMDCs transplantation into FcgRIIB KO mice attenuates
allergic airway inflammation by anti-OVA IgG1
In order to examine how DCs are related to allergic air-
way inflammation, BMDCs from WT mice were
intravenously transplanted into FcgRIIB KO mice and the
efficacy of anti-OVA IgG1 was analysed by BAL fluid.
Total cells and eosinophils were lower in FcgRIIB KO
mice transplanted intravenously and instilled with anti-
OVA IgG1 compared to FcgRIIB KO mice instilled with
PBS and anti-OVA IgG1, showing that WT BMDCs
restored the effect of anti-OVA IgG1 on airway inflam-
mation (Figure 5). These data indicate that anti-OVA
Figure 1 Anti-OVA IgG inhibited allergic airway inflammation of WT mice by BAL fluid, histopathology and AHR. A, Total cell counts
and cellular composition of BAL fluid obtained from OVA-sensitized WT mice instilled with PBS, anti-OVAIgG1 and IgG2a, and non-specific IgG. *:
p < 0.01 vs. WT/PBS; †: p < 0.05 vs. WT/IgG2a; TC: total cells; Eo: eosinophils; MF: macrophages; Neu: neutrophils; Lym: lymphocytes. B, Th1 and
Th2 cytokine levels in BAL fluid after instillation of PBS (black bars), anti-OVA IgG1 (gray bars) or anti-OVA IgG2a (dot bars) are shown. *: p < 0.05
vs. WT/PBS. C, Histological examination of lung tissues instilled with PBS and anti-OVA IgG subclasses. Micrographs (low and high magnification,
×100 and ×400, respectively) depict lung sections stained with H&E. D, AHR after instillation with PBS and anti-OVA IgG subclasses. Increased
Penh in response to inhaled methacholine was measured. Results are expressed as values relative to baseline. Data show means ± SEM pooled
from three independent experiments with 4-12 mice/group.
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IgG1 attenuated allergic airway inflammation via FcgRIIB
in transplanted BMDCs.
Discussion
We demonstrated that antigen-specific IgG ameliorated
airway inflammation via FcgRIIB on CD11c+ APCs
including DCs, but non-specific IgG did not. DCs are
the most potent APCs, and play a crucial role in pro-
moting development of active immunity in allergic air-
way inflammation. Immature DCs sense the presence of
invading antigens and process the antigen intracellularly
in inflamed tissue, developing into mature DCs with
upregulated expression of MHC and costimulatory
molecules in inflammatory microenvironments [19-21,
32]. Subsequently, mature DCs home into secondary
lymphoid tissue, where they present the processed
antigens to naïve T-cells to generate effector T-cells
[19-21,32]. In vitro, there have been some reports that
human IgG inhibits the differentiation and maturation
of human monocyte-derived DCs [33,34]. Boruchov et
al. showed that the DCs maturation marker CD83 and
the costimulatory molecule CD86 on soluble human
IgG-treated DCs are decreased [34]. In addition,
although there are have been reports on the relationship
between IgG and DCs in vitro, there have been no pre-
vious studies of antigen-specific IgG and DCs in murine
asthmatic model. Therefore, we examined the role of
DCs and the mechanisms that antigen-specific IgG sup-
pressed allergic airway inflammation in mice.
CD11c+ MHC class II+ cells were previously con-
firmed as DCs, and were recently described as CD103
+CD11b- and CD103-CD11b+ subpopulations [35]. We
also used lung-derived CD11c+ APCs to examine the
mechanisms related to allergen-specific IgG and DCs. In
the present study, anti-OVA IgG1 reduced the number
Figure 2 The numbers of OVA transport to thoracic lymph
nodes with anti-OVA IgG1 instillation reduced compared with
PBS. (A) Fluorescence microscopy findings of thoracic lymph nodes
by instillation of OVA-fluorescein conjugate in OVA-sensitized WT
mice instilled with PBS and anti-OVA IgG1. (B) The CD11c+ MHC
class II+ cells which intaken fluorescein-conjugated OVA in thoracic
lymph nodes was analysed by flow cytometry. Data show mean
value pooled from three independent experiments.
Figure 3 MHC class II expression on lung-derived CD11c+ APCs
with anti-OVA IgG1 instillation reduced compared with PBS.
MHC class II expression on lung-derived CD11c+ APCs purified from
naïve mice, mice instilled with PBS or anti-OVA IgG1 were analysed.
Values inside histograms represent the percentage of MHC class II
expression on lung-derived CD11c+ APCs. The numbers on the
histogram show mean value of each percentage of gated cells from
three independent experiments.
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of the fluorescein-positive CD11c+ MHC class II+ cells
in thoracic lymph nodes compared with PBS instilled
group, showing that anti-OVA IgG1 instillation in aller-
gic inflammation reduced transport of OVA. Our find-
ings also demonstrated that MHC class II expression on
CD11c+ APCs was decreased in anti-OVA IgG1 instilled
mice. Moreover, WT-derived BMDCs transplantation
revealed the dependence of the anti-OVA IgG1 effect
on FcgRIIB on transplanted BMDCs. In addition, CD11c+
DCs, not macrophages, have been reported to play cru-
cial role in development of allergen-induced airway
inflammation [21]. From above, anti-OVA IgG1 instilla-
tion suggested to modify the functions of CD11c+ lung
APCs, including DCs. In vitro, we also indicated that
anti-OVA IgG1 significantly ameliorated the activation of
DCs, showing a reduction of the proliferation of T cells.
Our study thus demonstrated for the first time that anti-
gen-specific IgG ameliorates the activation and matura-
tion of CD11c+ APCs including DCs in allergic mice and
in vitro.
Mice have four different classes of FcRs; FcgRI, FcgRII,
FcgRIII and FcgRIV. Functionally, FcRs are classified in
two types: activating FcgRs that possess an ITAM in the
cytoplasmic domain, including FcgRI, FcgRIIA, FcgRIII,
FcgRIV [13,15]; and inhibitory FcgRs such as FcgRIIB,
which exerts activity via ITIM. The composite expres-
sion of activating and inhibitory FcgRs thus regulates
the immune response [15]. Also, in the previous studies,
the presence of FcgRI-III on pulmonary macrophages
and high RNA levels of FcgRIIB relative to FcgRI and
FcgRIII on lung-derived CD11c+ MHC class II+ DCs are
demonstrated [35]. In a previous study, Kitamura et al.
reported that expression of FcgRs on DCs is important
during the sensitization for the development of allergen-
induced AHR and inflammation [22]. In vitro experi-
ments, expression levels of CD86 and MHC class II
were shown to be higher in BMDC in mice loaded with
OVA-immune complex (IC) than in those loaded with
OVA; however, no significant differences were seen in
FcgR KO mice [36], suggesting more efficient matura-
tion by OVA-IC than by OVA alone through FcgRs on
DCs. Moreover, allergen-specific IgG, which is generated
during sensitization, lead to IC formation upon antigen
challenge and result in enhanced FcgR-mediated antigen
presentation as previously described [35]. However, in
our study, intratracheal instillation of anti-OVA IgG1
Figure 4 Anti-OVA IgG1 inhibited the cell proliferation of
BMDCs in vitro. BMDCs (2 × 104 cells per well) were purified from
WT mice and pulsed with OVA peptide (20 μM) or anti-OVA IgG1
(0.1 mg/ml) containing the same amount of OVA. Negative control
means no addition of OVA peptide in culture medium. Cells were
washed and used to stimulate CD4+ T-cells (2 × 105 cells per well).
The proliferation of T cells after DCs treatment with anti-OVA IgG1
was quantified in duplicate by measuring the optical density using
the WST-8 cell-counting kit after 48 h. Data show means ± SEM.
*p < 0.05.
Figure 5 Anti-OVA IgG1 increased allergic airway inflammation
in FcgRIIB KO mice, and BMDCs transplantation reversed its
effects. A, Total cell, eosinophil and the others cell counts of BAL
fluid obtained from OVA-sensitized and challenged FcgRIIB KO mice
(IIBKO) instilled with PBS or anti-OVAIgG1. Moreover, FcgRIIB KO
mice intravenously transplanted with WT-derived BMDCs (IIBKO/DC
i.v. IgG1) were sensitized and challenged with OVA, and instilled
intratracheally with anti-OVA IgG1. The number of BAL fluid was
analysed. Data show mean ± SEM. #: p < 0.05 vs. WT/PBS, ‡: p <
0.05 vs. IIBKO/PBS. B, Histological examination of lung tissues of
FcgRIIB KO mice instilled with PBS and anti-OVA IgG1. Micrographs
(high magnification, ×400) depict lung sections stained with H&E.
Ishikawa et al. Respiratory Research 2011, 12:42
http://respiratory-research.com/content/12/1/42
Page 7 of 10
separately from OVA ameliorated allergic airway inflam-
mation. This difference may be the result of differences
in FcR affinity for IgG alone or IC. FcgR may more
readily ligate to IC, while FcgRIIB may more readily
ligate to separate IgG than IC. In the previous studies,
soluble monomeric IgG decreased FcgRIIA expression
and increased FcgRIIB on immature DCs in human per-
ipheral blood mononuclear cells when soluble mono-
meric IgG was added to cultures of immature DCs [34].
Also, high expression levels of FcgRIIB in immature
human DCs were detected, while in mature DCs
FcgRIIB was markedly down-regulated as previously
described [37], indicating that engagement of FcgRIIB by
IC can inhibit DCs activation and antigen uptake. In
mice, we suggested that FcgRIIB on immature DCs
increases during sensitization by instillation of anti-
OVA IgG1 and are more easily ligated with anti-OVA
IgG1 alone. Moreover, Hartwig et al. demonstrated that
anti-OVA IgG alone ameliorated the number of total
cells and eosinophils in BAL, and peribronchial and
perivascular cell counts of inflammatory cells in histol-
ogy when compared with OVA-challenged mice [35]. In
this point, their results correspond to our results that
anti-OVA IgG alone ameliorated allergic airway inflam-
mation and AHR, suggesting that anti-OVA IgG1
directly binds with FcgRIIB on DCs during allergic air-
way inflammation.
Various studies have examined the role of FcgRIIB in
down-regulating specific allergic inflammatory cells in
vitro. Dharajiya et al. also reported that FcgRIIB inhib-
ited allergic lung inflammation in a murine model of
allergic asthma, although our protocol was different
from their properties of the challenged allergen or the
methods of challenge. They examined the role of
FcgRIIB in allergic lung inflammation using FcgRIIB KO
mice sensitized to and challenged with ragweed. Rag-
weed challenge in sensitized mice up-regulated FcgRIIB
in the lungs; however, disruption of the IFN-g gene
abrogated this up-regulation. These results indicate that
ragweed challenge up-regulates FcgRIIB in the lungs via
IFN-g and Th1-dependent mechanisms. They indicated
that FcgRIIB physiologically regulated allergic airway
inflammation by the up-regulation of FcgRIIB on pul-
monary CD14+/MHC class II+ mononuclear cells and
CD11c+ cells by an IFN-g and Th1-dependent mechan-
ism [38]. Moreover, we have previously demonstrated
that intravenous IgG ameliorated allergic airway inflam-
mation via FcgRIIB on CD11c+ DCs [39]. In another
study, Sehra et al. reported that airway IgG counteracted
allergen-triggered pulmonary inflammation and showed
that this treatment increased Th1 reactivity and IFN-g
levels in BAL [40]. They showed that airway IgG appli-
cation increased allergen capture by activating FcgR on
alveolar macrophages and led to increased Th1 reactivity
and IFN-g, resulting in suppression of airway eosinophil
infiltration. In this study, antigen-specific IgG was found
to ameliorate antigen uptake and presentation by DCs,
and suppress allergic airway inflammation via FcgRIIB,
not FcgR, on DCs. In addition, anti-OVA IgG1 instilla-
tion significantly decreased IL-4, IL-5, and IL-13 cyto-
kine levels and increased IFN-g in BAL fluid compared
with PBS. These results indicated that intratracheal
instillation of anti-OVA IgG1 alone caused a shift from
Th2 to Th1 in allergic airway inflammation. We indicate
that anti-OVA IgG1 attenuate the activation of DCs
which induces Th2 response, by binding to FcgRIIB on
DCs.
We demonstrated that intratracheal instillation of
antigen-specific IgG ameliorated allergic airway inflam-
mation via FcgRIIB on CD11c+ APCs including DCs.
Mouse IgG1 is reported to have higher affinity for
FcgRIIB than IgG2a [16]. We found that anti-OVA IgG1
most strongly ameliorated airway inflammation among
the anti-OVA IgG subclasses in total cells, eosinophils,
Th2 cytokine levels in BAL fluid, AHR, and histology.
The present studies in FcgRIIB KO mice instilled with
PBS didn’t show increased inflammation compared with
WT asthmatic mice. However, our previous studies
demonstrated that FcgRIIB KO mice instilled with PBS
showed allergic airway inflammation as WT asthmatic
mice [39]. Challenged FcgRIIB KO mice instilled with
PBS have increased inflammation, indicating that the
balance between FcgRIIB and FcgR which existed in its
cytoplasm had a tendency to FcgR of activating type
FcR. Moreover, FcgRIIB KO mice instilled with anti-
OVA IgG1 significantly deteriorated airway inflamma-
tion in BAL fluid and histopathology. These data suggest
the balance with a further tendency to activating FcgR
caused by intratracheal instillation of anti-OVA IgG1 in
FcgRIIB KO.
In a murine model, intratracheally transplanted mye-
loid DCs from the airway are known to induce Th2
reactivity after antigen sensitization and inhalation, and
leading to eosinophilic airway inflammation [41].
In vitro, we also indicated that anti-OVA IgG1 signifi-
cantly ameliorated the activation of DCs, showing a
reduction of the proliferation of T cells. Furthermore,
we demonstrated that intravenous transplantation of
BMDCs and intratracheal instillation of anti-OVA IgG1
ameliorated the cellular infiltration to BAL fluid com-
pared to FcgRIIB KO mice instilled with PBS and anti-
OVA IgG1, showing that i.v. transplanted BMDCs had
its local effects on allergic inflammation. Our data in
vivo and in vitro showed that myeloid DCs play impor-
tant roles to develop Th2 response inflammation
as previously reported. Our findings suggested that
Ishikawa et al. Respiratory Research 2011, 12:42
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antigen-specific IgG ameliorated the antigen transport-
ing and presenting capacity on CD11c+ APCs including
DCs, resulting in attenuating allergic airway inflamma-
tion via FcgRIIB on DCs by shifting from Th2 to Th1
immune response.
Conclusions
We concluded that anti-OVA IgG ameliorated allergic
airway inflammation via FcgRIIB on DCs in murine
asthmatic model. Further studies for the function of
FcgRIIB in human airway inflammation would be
required. Our findings have important implications for
elucidating the pathophysiology of asthmatic diseases
and engineering agents to target IgG-FcR on DCs.
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